Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Strata Critical Medical, Inc.NASDAQ: SRTA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $3.06M rose 80.3% year over year, ahead of the +53.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at +12.7% a year.
Context
- Depreciation & amortization amounted to 4.2% of revenue in FY2025, up 1.8 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +80.3% holds above the trailing-twelve-month pace of +53.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 8.19M USD
- Year-over-year change
- +37.3%
- 4-year CAGR
- +92.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.19M | +37.3% |
| FY2024 | 2024-12-31 | 5.96M | -16.2% |
| FY2023 | 2023-12-31 | 7.11M | +24.2% |
| FY2022 | 2022-12-31 | 5.73M | +860.6% |
| FY2021 | 2021-09-30 | 596K | — |
Depreciation & Amortization vs competitors
How SRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +53.2% is the highest of 9, against a peer median of -10.6%.
- Depreciation & amortization amounts to 3.7% of revenue for SRTA, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $146.4M USD | +5.3% | +24.0% | 9.5% | |
| LTM Mar 2026 | $31.79M USD | -11.3% | -8.7% | 3.6% | |
| LTM Mar 2026 | $26.47M USD | -14.4% | +6.8% | 14.5% | |
| LTM Mar 2026 | $22.52M USD | -11.6% | +0.7% | 5.9% | |
| LTM Feb 2026 | $17.13M USD | +3.6% | -0.4% | 4.4% | |
| LTM Mar 2026 | $12.79M USD | — | +7.8% | 14.5% | |
| LTM Mar 2026 | $12.36M USD | +1.7% | +5.3% | 2.8% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $9.29M USD | +53.2% | +12.7% | 3.7% |
| LTM Mar 2026 | $9.18M USD | -10.2% | -13.1% | 1.1% | |
| LTM Mar 2026 | $5.39M USD | -11.0% | +7.8% | 0.4% | |
| LTM Mar 2026 | £2.7M GBP | — | -4.3% | — | |
| Peer median (excluding SRTA) | — | -10.6% | +3.0% | 4.4% | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | 41.35M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 8.19M |
| Deferred Income Tax | (3.64M) | (772K) | (1.47M) | (255K) | 432K |
| Stock-Based Compensation | 9.62M | 8.28M | 12.5M | 19.89M | 17.83M |
| Change in Working Capital | (2.2M) | (17K) | (6.74M) | (3.01M) | (9.08M) |
| Accounts Receivables | (414K) | (5.35M) | (10.25M) | (998K) | (12.03M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 9.9M | 0 | 0 | 0 |
| Other Working Capital | (1.79M) | (4.57M) | 3.52M | (2.01M) | 2.95M |
| Other Non-Cash Items | 20.06M | (23.08M) | 12.32M | 2.2M | (107.63M) |
| Operating Cash Flow | (15.62M) | (37.13M) | (32.35M) | (2.52M) | (48.91M) |
| Capital Expenditures | (801K) | (730K) | (2.11M) | (32.99M) | (11.01M) |
| Acquisitions (Net) | (23.07M) | (48.1M) | (39K) | (2.23M) | (69.35M) |
| Purchases of Investments | (308.77M) | (228.21M) | (265.97M) | (143.26M) | (146.26M) |
| Sales of Investments | 11.3M | 356.38M | 285.07M | 177.45M | 296.36M |
| Other Investing Activities | (504K) | 0 | 138K | (2.11M) | (1.42M) |
| Investing Cash Flow | (321.34M) | 79.34M | 17.09M | (1.02M) | 69.75M |
| Debt Repayment | (1.17M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 119.63M | 87K | 0 | 0 | 193K |
| Common Stock Repurchased | 0 | 0 | 0 | (244K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 213.79M | (1.17M) | (76K) | (5.52M) | (9.11M) |
| Financing Cash Flow | 332.26M | (1.08M) | (76K) | (5.76M) | (8.91M) |
| Effect of Forex Changes | 10.97M | (4.29M) | (66K) | (80K) | (339K) |
| Net Change in Cash | (4.69M) | 36.84M | (15.4M) | (9.37M) | 11.59M |
| Free Cash Flow | (16.42M) | (37.86M) | (34.46M) | (35.51M) | (59.92M) |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.